MiR-26a/miR-26b Represses Tongue Squamous Cell Carcinoma Progression by Targeting PAK1

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2020 Mar 20

PMID 32190006

Citations 14

Authors

Zhenxing Wei

Kunpeng Chang

Chongsheng Fan

Yang Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Tongue squamous cell carcinoma (TSCC) is the most common oral malignancy. Previous studies found that microRNA (miR)-26a and miR-26b were downregulated in TSCC tissues. The current study was designed to explore the effects of miR-26a/miR-26b on TSCC progression and the potential mechanism.

Methods: Expression of miR-26a, miR-26b and p21 Activated Kinase 1 (PAK1) in TSCC tissues and cell lines was detected by reverse transcription- quantitative polymerase chain reaction (RT-qPCR). Flow cytometry analysis was performed to examine cell cycle and apoptosis. Transwell assay was conducted to evaluate the migrated and invasive abilities of SCC4 and Cal27 cells. In addition, western blot assay was employed to analyze the protein level. Glucose assay kit and lactate assay kit were utilized to analyze glycolysis. Dual-luciferase reporter and RNA immunoprecipitation (RIP) assays were applied to explore the relationship between miR-26a/miR-26b and PAK1. Xenograft tumor model was constructed to explore the role of miR-26a/miR-26b in vivo.

Results: Both miR-26a and miR-26b were underexpressed, while PAK1 was highly enriched in TSCC. Overexpression of miR-26a and miR-26b inhibited TSCC cell cycle, migration invasion and glycolysis, while promoted cell apoptosis. Both miR-26a and miR-26b directly targeted and negatively regulated PAK1 expression. Introduction of PAK1 partially reversed miR-26a/miR-26b upregulation-mediated cellular behaviors in TSCC cells. Gain of miR-26a/miR-26b blocked TSCC tumor growth in vivo.

Conclusion: MiR-26a/miR-26b repressed TSCC progression via targeting PAK1 in vitro and in vivo, which enriched our understanding about TSCC development and provided new insights into the its treatment.

Citing Articles

Molecular detection of exosomal miRNAs of blood serum for prognosis of colorectal cancer.

Bakhsh T, Alhazmi S, Farsi A, Yusuf A, Alharthi A, Qahl S Sci Rep. 2024; 14(1):8902.

PMID: 38632250 PMC: 11024162. DOI: 10.1038/s41598-024-58536-3.

Twist1 as a target for prevention of cutaneous squamous cell carcinoma.

Wang T, Rho O, Eguiarte-Solomon F, DiGiovanni J Mol Carcinog. 2022; 62(1):62-76.

PMID: 36373194 PMC: 9772054. DOI: 10.1002/mc.23482.

The circular RNA circ_0099630/miR-940/receptor-associated factor 6 regulation cascade modulates the pathogenesis of periodontitis.

Zhao X, Ao C, Yan Y J Dent Sci. 2022; 17(4):1566-1576.

PMID: 36299308 PMC: 9588814. DOI: 10.1016/j.jds.2022.04.005.

The Functional Mechanism of MicroRNA in Oral Lichen Planus.

Li Y, He Y, Xiang J, Feng L, Wang Y, Chen R J Inflamm Res. 2022; 15:4261-4274.

PMID: 35923905 PMC: 9342247. DOI: 10.2147/JIR.S369304.

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Thomaidou A, Batsaki P, Adamaki M, Goulielmaki M, Baxevanis C, Zoumpourlis V Int J Mol Sci. 2022; 23(15).

PMID: 35897831 PMC: 9367895. DOI: 10.3390/ijms23158257.

References

Ma L, Wang Q, Gong Z, Xue L, Zuo Z . Long noncoding RNA GIHCG enhanced tongue squamous cell carcinoma progression through regulating miR-429. J Cell Biochem. 2018; 119(11):9064-9071. DOI: 10.1002/jcb.27164. View

Karatas O, Oner M, Abay A, Diyapoglu A . MicroRNAs in human tongue squamous cell carcinoma: From pathogenesis to therapeutic implications. Oral Oncol. 2017; 67:124-130. DOI: 10.1016/j.oraloncology.2017.02.015. View

Jia L, Wei S, Gan Y, Guo Y, Gong K, Mitchelson K . Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma. Int J Cancer. 2013; 135(10):2282-93. DOI: 10.1002/ijc.28667. View

Xu Y, Song Y, Huang Z, Zhang H, Chen M . MicroRNA-26a inhibits multiple myeloma cell growth by suppressing cyclin-dependent kinase 6 expression. Kaohsiung J Med Sci. 2019; 35(5):277-283. DOI: 10.1002/kjm2.12057. View

Kumar R, Gururaj A, Barnes C . p21-activated kinases in cancer. Nat Rev Cancer. 2006; 6(6):459-71. DOI: 10.1038/nrc1892. View

Li D, Liu K, Li Z, Wang J, Wang X . miR-19a and miR-424 target TGFBR3 to promote epithelial-to-mesenchymal transition and migration of tongue squamous cell carcinoma cells. Cell Adh Migr. 2017; 12(3):236-246. PMC: 6149514. DOI: 10.1080/19336918.2017.1365992. View

Chen J, Xu Y, Tao L, Pan Y, Zhang K, Wang R . MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2. Cell Physiol Biochem. 2017; 41(2):583-597. DOI: 10.1159/000457879. View

Di Leva G, Garofalo M, Croce C . MicroRNAs in cancer. Annu Rev Pathol. 2013; 9:287-314. PMC: 4009396. DOI: 10.1146/annurev-pathol-012513-104715. View

Zhao X, Yuan Q, Mu D, Sun D, Bo Q, Pan G . MicroRNA-26a inhibits proliferation by targeting high mobility group AT-hook 1 in breast cancer. Int J Clin Exp Pathol. 2015; 8(1):368-73. PMC: 4348937. View

10.

Cao J, Guo T, Dong Q, Zhang J, Li Y . miR-26b is downregulated in human tongue squamous cell carcinoma and regulates cell proliferation and metastasis through a COX-2-dependent mechanism. Oncol Rep. 2014; 33(2):974-80. DOI: 10.3892/or.2014.3648. View

11.

Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y . miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett. 2013; 587(15):2467-73. DOI: 10.1016/j.febslet.2013.06.021. View

12.

Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li C . Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018; 77:121-129. DOI: 10.1016/j.humpath.2018.04.002. View

13.

Du J, Wang L, Wang Q, Yu L . miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells. Oncol Rep. 2015; 33(4):1890-8. DOI: 10.3892/or.2015.3797. View

14.

Liang J, Han B, Zhang Y, Yue Q . Numb inhibits cell proliferation, invasion, and epithelial-mesenchymal transition through PAK1/β-catenin signaling pathway in ovarian cancer. Onco Targets Ther. 2019; 12:3223-3233. PMC: 6497004. DOI: 10.2147/OTT.S194725. View

15.

Li Y, Sun Z, Liu B, Shan Y, Zhao L, Jia L . Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. Cell Death Dis. 2017; 8(6):e2892. PMC: 5520934. DOI: 10.1038/cddis.2017.281. View

16.

Zhu M, Zhang C, Chen D, Chen S, Zheng H . lncRNA potentiates the progression of tongue squamous cell carcinoma through regulating -PAK1 pathway. Onco Targets Ther. 2019; 12:1365-1377. PMC: 6388959. DOI: 10.2147/OTT.S192069. View

17.

Shang Q, Yang Z, Jia R, Ge S . The novel roles of circRNAs in human cancer. Mol Cancer. 2019; 18(1):6. PMC: 6325800. DOI: 10.1186/s12943-018-0934-6. View

18.

Yu X, Li Z . MicroRNA expression and its implications for diagnosis and therapy of tongue squamous cell carcinoma. J Cell Mol Med. 2015; 20(1):10-6. PMC: 4717854. DOI: 10.1111/jcmm.12650. View

19.

Ye D, Field J . PAK signaling in cancer. Cell Logist. 2012; 2(2):105-116. PMC: 3490961. DOI: 10.4161/cl.21882. View

20.

Zhan M, Yu X, Tang J, Zhou C, Wang C, Yin Q . MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1. Cell Death Dis. 2017; 8(1):e2529. PMC: 5386359. DOI: 10.1038/cddis.2016.440. View